Known targets — ChEMBL curated mechanism
PPARDPTGS1PTGS2dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Lysine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 2/20 | 0.95 |
| ▸ | ARG2 | P78540 | 4/20 | 0.57 |
| ▸ | ARG1 | P05089 | 3/20 | 0.57 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.56 |
| ▸ | NOS2 | P35228 | 5/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.50 |
| ▸ | NOS1 | P29475 | 3/20 | 0.50 |
| ▸ | NOS3 | P29474 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | GRM8 | O00222 | 1/20 | 0.50 |
| ▸ | GRM6 | O15303 | 1/20 | 0.50 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.50 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.50 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.50 |
| ▸ | GRM5 | P41594 | 1/20 | 0.50 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.50 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.50 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lysine SCHEMBL374727 | 1.00 | GSR (0.95) | GSRARG2ARG1RNPEPNOS2 | |
| Lysine SCHEMBL374726 | 1.00 | GSR (0.95) | GSRARG2ARG1RNPEPNOS2 | |
| Lysine SCHEMBL5489655 | 0.98 | GSR (0.91) | GSRARG2ARG1RNPEPNOS2 | |
| Lysine SCHEMBL6442716 | 0.98 | GSR (0.91) | GSRARG2ARG1RNPEPNOS2 | |
| Lysine SCHEMBL7343 | 0.98 | GSR (1.00) | GSRARG2ARG1RNPEPNOS2 | |
| Lysine SCHEMBL20362357 | 0.98 | GSR (1.00) | GSRARG2ARG1RNPEPNOS2 | |
| Lysine SCHEMBL1000151 | 0.98 | GSR (1.00) | GSRARG2ARG1RNPEPNOS2 | |
| Lysine SCHEMBL12867528 | 0.98 | GSR (1.00) | GSRARG2ARG1RNPEPNOS2 | |
| Lysine SCHEMBL1645 | 0.98 | GSR (1.00) | GSRARG2ARG1RNPEPNOS2 | |
| Lysine SCHEMBL9439278 | 0.98 | GSR (1.00) | GSRARG2ARG1RNPEPNOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024063523-A1 | BIOMARKER FOR DIAGNOSING RESISTANCE TO ANTICANCER DRUG IN BLADDER CANCER, AND USE THEREOF | 동아대학교 산학협력단 | 2024-03-28 | — | — | WO | disclosed |
| WO-2023219443-A1 | BIOMARKER FOR METASTATIC BLADDER CANCER | 동아대학교 산학협력단 | 2023-11-16 | — | — | WO | disclosed |
| EP-3986999-A1 | CELL SCAFFOLD COMPRISING AN ELECTRONIC CIRCUIT | President and Fellows of Harvard College (US) | 2022-04-27 | — | — | EP | disclosed |
| CN-114341154-A | Substrate for tryptase Activity measurement | 国立大学法人东京农工大学 | 2022-04-12 | — | — | CN | disclosed |
| CN-113631718-A | Compositions and methods for compartment-specific cargo delivery | 旗舰先锋创新V股份有限公司 | 2021-11-09 | — | — | CN | disclosed |
| CN-113613633-A | Fusogenic liposome compositions for CNS delivery | 旗舰先锋创新V股份有限公司 | 2021-11-05 | — | — | CN | disclosed |
| CN-110982788-B | Method for inducing transdifferentiation of satellite glial cells into neurons | 昆明医科大学 | 2021-07-06 | — | — | CN | disclosed |
| CN-112955174-A | Fusogenic liposome compositions and uses thereof | 旗舰先锋创新V股份有限公司 | 2021-06-11 | — | — | CN | disclosed |
| WO-2021045182-A1 | TRYPTASE ACTIVITY MEASUREMENT SUBSTRATE | 国立大学法人東京農工大学 | 2021-03-11 | — | — | WO | disclosed |
| CN-112272706-A | Compositions and methods for membrane protein delivery | 旗舰先锋创新V股份有限公司 | 2021-01-26 | — | — | CN | disclosed |
| EP-1751613-A2 | PHOTONIC CRYSTAL SENSORS | Agilent Technologies, Inc. (US) | 2007-02-14 | — | — | EP | disclosed |
| EP-1725235-A1 | PIPERIDINE DERIVATIVES USEFUL AS CCR3 ANTAGONISTS | SCHERING CORPORATION (US) | 2006-11-29 | — | — | EP | disclosed |
| WO-2006098844-A1 | APPARATUS FOR SINGLE NANOPARTICLE DETECTION | AGILENT TECHNOLOGIES, INC. (US) | 2006-09-21 | — | — | WO | disclosed |
| WO-2005089129-A2 | PHOTONIC CRYSTAL SENSORS | AGILENT TECHNOLOGIES, INC. (US) | 2005-09-29 | — | — | WO | disclosed |
| US-20050201660-A1 | Apparatus for single nanoparticle detection | AGILENT TECHNOLOGIES, INC. | 2005-09-15 | — | — | US | disclosed |
| US-20050200942-A1 | Photonic crystal sensors | AGILENT TECHNOLOGIES, INC. | 2005-09-15 | — | — | US | disclosed |
| WO-2005077369-A1 | PIPERIDINE DERIVATIVES USEFUL AS CCR3 ANTAGONISTS | SCHERING CORPORATION (US) | 2005-08-25 | — | — | WO | disclosed |
| US-20050182095-A1 | Piperdine derivatives useful as CCR3 antagonists | SCHERING CORPORATION | 2005-08-18 | — | — | US | disclosed |
| CN-1193818-C | Silicone dioxide magnetic microsphere and its preparation method | UNIV EAST CHINA SCIENCE & TECH (CN) | 2005-03-23 | — | — | CN | disclosed |
| CN-1380133-A | Silicone dioxide magnetic microsphere and its preparation method | UNIV HUADONG SCIENCE & ENG (CN) | 2002-11-20 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182095-A1 | Piperdine derivatives useful as CCR3 antagonists | CCR3, CCR4, CCR6 | GSR 4619/4885ARG2 1362/4885ARG1 344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.